NZ609916A - Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof - Google Patents

Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

Info

Publication number
NZ609916A
NZ609916A NZ60991611A NZ60991611A NZ609916A NZ 609916 A NZ609916 A NZ 609916A NZ 60991611 A NZ60991611 A NZ 60991611A NZ 60991611 A NZ60991611 A NZ 60991611A NZ 609916 A NZ609916 A NZ 609916A
Authority
NZ
New Zealand
Prior art keywords
seq
hla
binding peptides
prostate
methods
Prior art date
Application number
NZ60991611A
Other languages
English (en)
Inventor
Toni Weinschenk
Peter Lewandrowski
Hans-Georg Rammensee
Stefan Stevanovic
Cécile GOUTTEFANGEAS
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/069675 external-priority patent/WO2011073215A2/fr
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of NZ609916A publication Critical patent/NZ609916A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ60991611A 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof NZ609916A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2010/069675 WO2011073215A2 (fr) 2009-12-14 2010-12-14 Peptides se liant aux hla, dérivés de molécules antigéniques associées à la prostate, et leurs procédés d'utilisation
PCT/EP2011/070024 WO2012079878A2 (fr) 2010-12-14 2011-11-14 Peptides se liant au hla dérivés de molécules antigéniques associées à la prostate et procédés d'utilisation associés

Publications (1)

Publication Number Publication Date
NZ609916A true NZ609916A (en) 2015-03-27

Family

ID=44983532

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ60991611A NZ609916A (en) 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

Country Status (9)

Country Link
JP (1) JP6032853B2 (fr)
KR (1) KR20130126671A (fr)
CN (1) CN103547283A (fr)
AU (1) AU2011344652B2 (fr)
CA (1) CA2821582A1 (fr)
MX (1) MX2013006758A (fr)
NZ (1) NZ609916A (fr)
SG (1) SG191154A1 (fr)
WO (1) WO2012079878A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
MX2016013559A (es) * 2014-04-16 2017-04-27 Biocon Ltd Formulaciones de proteina estables que comprenden un exceso molar de sorbitol.
US10639329B2 (en) * 2015-06-12 2020-05-05 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
EP4317432A3 (fr) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH Récepteurs de lymphocytes t à appariement amélioré
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
SI3580561T1 (sl) * 2017-02-12 2024-04-30 Biontech Us Inc. Metode, osnovane na hla, in njihove sestave ter uporabe
KR102215578B1 (ko) * 2019-03-28 2021-02-15 한국과학기술연구원 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2394741A1 (fr) * 1999-12-21 2001-06-28 Epimmune Inc. Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2003217421A1 (en) * 2002-02-19 2003-09-09 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
EP2181595A1 (fr) * 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Antigène spécifique de tumeurs, peptides associés et utilisation de ceux-ci en tant que vaccins antitumoraux
AU2003302820A1 (en) * 2002-12-05 2004-06-30 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins
WO2005033265A2 (fr) * 2003-04-25 2005-04-14 Epimmune Inc. Constructions multi-epitope optimisees et leurs utilisations
WO2006023598A2 (fr) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Peptides restreints par mhc classe ii derives d'antigenes specifiques a la prostate et leur utilisation dans des vaccins destines a traiter ou a prevenir le cancer de la prostate
DE602004019215D1 (de) 2004-10-02 2009-03-12 Immatics Biotechnologies Gmbh Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
PT1806358E (pt) 2005-09-05 2010-05-28 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
PT2113253E (pt) * 2008-04-30 2010-06-15 Immatics Biotechnologies Gmbh Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
NO2119726T3 (fr) * 2008-05-14 2015-05-23
PT2172211E (pt) * 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer

Also Published As

Publication number Publication date
WO2012079878A2 (fr) 2012-06-21
CA2821582A1 (fr) 2012-06-21
AU2011344652A1 (en) 2013-05-23
SG191154A1 (en) 2013-07-31
AU2011344652B2 (en) 2015-11-19
KR20130126671A (ko) 2013-11-20
WO2012079878A3 (fr) 2012-08-09
CN103547283A (zh) 2014-01-29
JP6032853B2 (ja) 2016-11-30
MX2013006758A (es) 2013-08-01
JP2014502961A (ja) 2014-02-06

Similar Documents

Publication Publication Date Title
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
EP3712165A3 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ601345A (en) Combination adjuvant formulation
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
MX337436B (es) Proteina de funsion anticancer.
NZ708990A (en) Method for activating helper t cell
NZ702839A (en) Vaccine and methods to reduce campylobacter infection
JP2014502961A5 (fr)
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
EP4269562A3 (fr) Molécules de liaison à l'antigène et procédés d'utilisation associés
NZ596501A (en) Casb7439 constructs
IN2014DN09963A (fr)
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
MY166516A (en) Tomm34 peptides and vaccines including the same
EP3556857A3 (fr) Peptides cdc45l et vaccins les comportant
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
GB201018125D0 (en) Peptide

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2016 BY PAVIS EG

Effective date: 20151102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2017 BY PAVIS GMBH

Effective date: 20161103

LAPS Patent lapsed